|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Liu N, Wu C, Jia R, Cai G, Wang Y, Zhou L,
Ji Q, Sui H, Zeng P, Xiao H, et al: Traditional Chinese medicine
combined with chemotherapy and cetuximab or bevacizumab for
metastatic colorectal cancer: A randomized, double-blind,
placebo-controlled clinical trial. Front Pharmacol.
11(478)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Paldino E, Tesori V, Casalbore P,
Gasbarrini A and Puglisi MA: Tumor initiating cells and
chemoresistance: Which is the best strategy to target colon cancer
stem cells? Biomed Res Int. 2014(859871)2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Duffy A, Le J, Sausville E and Emadi A:
Autophagy modulation: A target for cancer treatment development.
Cancer Chemother Pharmacol. 75:439–447. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sui X, Chen R, Wang Z, Huang Z, Kong N,
Zhang M, Han W, Lou F, Yang J, Zhang Q, et al: Autophagy and
chemotherapy resistance: A promising therapeutic target for cancer
treatment. Cell Death Dis. 4(e838)2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Devenport SN and Shah YM: Functions and
implications of autophagy in colon cancer. Cells.
8(1349)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Di Leva G and Croce CM: miRNA profiling of
cancer. Curr Opin Genet Dev. 23:3–11. 2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Aguda BD: Modeling microRNA-transcription
factor networks in cancer. Adv Exp Med Biol. 774:149–167.
2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Baer C, Claus R and Plass C: Genome-wide
epigenetic regulation of miRNAs in cancer. Cancer Res. 73:473–477.
2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Song B, Wang Y, Xi Y, Kudo K, Bruheim S,
Botchkina GI, Gavin E, Wan Y, Formentini A, Kornmann M, et al:
Mechanism of chemoresistance mediated by miR-140 in human
osteosarcoma and colon cancer cells. Oncogene. 28:4065–4074.
2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Chai H, Liu M, Tian R, Li X and Tang H:
miR-20a targets BNIP2 and contributes chemotherapeutic resistance
in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta
Biochim Biophys Sin (Shanghai). 43:217–225. 2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Guo Y, Pang Y, Gao X, Zhao M, Zhang X,
Zhang H, Xuan B and Wang Y: MicroRNA-137 chemosensitizes colon
cancer cells to the chemotherapeutic drug oxaliplatin (OXA) by
targeting YBX1. Cancer Biomarkers. 18:1–9. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Qu J, Zhao L, Zhang P, Wang J, Xu N, Mi W,
Jiang X, Zhang C and Qu J: MicroRNA-195 chemosensitizes colon
cancer cells to the chemotherapeutic drug doxorubicin by targeting
the first binding site of BCL2L2 mRNA. J Cell Physiol. 230:535–545.
2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Liu J, Cheng LG and Li HG: LncRNA SNHG20
promoted the proliferation of glioma cells via sponging miR-4486 to
regulate the MDM2-p53 pathway. Eur Rev Med Pharmacol Sci.
23:5323–5331. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Asensio VJ, Tomás A, Iglesias A, de Llano
LP, Del Pozo V and Cosío BG: CHACOS study group. Eosinophilic COPD
patients display a distinctive serum mirna profile from asthma and
non-eosinophilic COPD. Arch Bronconeumol (Engl ED). 56:234–241.
2020.PubMed/NCBI View Article : Google Scholar : (In English,
Spanish).
|
|
16
|
Kim SH, Yun SW, Kim HR and Chae SA:
Exosomal microRNA expression profiles of cerebrospinal fluid in
febrile seizure patients. Seizure. 81:47–52. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hao H, Xia G, Wang C, Zhong F, Liu L and
Zhang D: miR-106a suppresses tumor cells death in colorectal cancer
through targeting ATG7. Med Mol Morphol. 50:76–85. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Xie Q, Liu Y and Li X: The interaction
mechanism between autophagy and apoptosis in colon cancer. Transl
Oncol. 13(100871)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Benson AB III, Venook AP, Cederquist L,
Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC,
Fichera A, et al: Colon cancer, version 1.2017, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
15:370–398. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Bosman FT, Carneiro F, Hruban RH and
Theise ND (eds.): WHO Classification of Tumors of the Digestive
System. Vol 3. 4th edition. IARC Press, Lyon, 2010.
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Song L, Zhou Z, Gan Y, Li P, Xu Y, Zhang
Z, Luo F, Xu J, Zhou Q and Dai F: Long noncoding RNA OIP5-AS1
causes cisplatin resistance in osteosarcoma through inducing the
LPAATbeta/PI3K/AKT/mTOR signaling pathway by sponging the
miR-340-5p. J Cell Biochem. 120:9656–9666. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Pan B, Chen Y, Song H, Xu Y, Wang R and
Chen L: Mir-24-3p downregulation contributes to VP16-DDP resistance
in small-cell lung cancer by targeting ATG4A. Oncotarget.
6:317–331. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lin C, Xie L, Lu Y, Hu Z and Chang J:
miR-133b reverses cisplatin resistance by targeting GSTP1 in
cisplatin-resistant lung cancer cells. Int J Mol Med. 41:2050–2058.
2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Qin X, Guo H, Wang X, Zhu X, Yan M, Wang
X, Xu Q, Shi J, Lu E, Chen W and Zhang J: Exosomal miR-196a derived
from cancer-associated fibroblasts confers cisplatin resistance in
head and neck cancer through targeting CDKN1B and ING5. Genome
Biol. 20(12)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Chan H, Pearson CS, Green CM, Li Z, Zhang
J, Belfort G, Shekhtman A, Li H and Belfort M: Exploring intein
inhibition by platinum compounds as an antimicrobial strategy. J
Biol Chem. 291:22661–22670. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Sun CY, Zhang QY, Zheng GJ and Feng B:
Phytochemicals: Current strategy to sensitize cancer cells to
cisplatin. Biomed Pharmacother. 110:518–527. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Oun R, Moussa YE and Wheate NJ:
Correction: The side effects of platinum-based chemotherapy drugs:
A review for chemists. Dalton Trans. 47(7848)2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Köberle B, Tomicic MT, Usanova S and Kaina
B: Cisplatin resistance: Preclinical findings and clinical
implications. Biochim Biophys Acta. 1806:172–182. 2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wu WK, Coffelt SB, Cho CH, Wang XJ, Lee
CW, Chan FK, Yu J and Sung JJ: The autophagic paradox in cancer
therapy. Oncogene. 31:939–953. 2012.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wang K: Autophagy and apoptosis in liver
injury. Cell Cycle. 14:1631–1642. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Bursch W: The autophagosomal-lysosomal
compartment in programmed cell death. Cell Death Differ. 8:569–581.
2001.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Shimizu S, Kanaseki T, Mizushima N, Mizuta
T, Arakawa-Kobayashi S, Thompson CB and Tsujimoto Y: Role of Bcl-2
family proteins in a non-apoptotic programmed cell death dependent
on autophagy genes. Nat Cell Biol. 6:1221–1228. 2004.PubMed/NCBI View Article : Google Scholar
|
|
36
|
He C and Levine B: The beclin 1
interactome. Curr Opin Cell Biol. 22:140–149. 2010.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Itakura E, Kishi C, Inoue K and Mizushima
N: Beclin 1 forms two distinct phosphatidylinositol 3-kinase
complexes with mammalian Atg14 and UVRAG. Mol Biol Cell.
19:5360–5372. 2008.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Deretic V: Autophagosome and phagosome.
Methods Mol Biol. 445:1–10. 2008.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Fu Ll, Cheng Y and Liu B: Beclin-1:
Autophagic regulator and therapeutic target in cancer. Int J
Biochem Cell Biol. 45:921–924. 2013.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Noguchi M, Hirata N, Tanaka T, Suizu F,
Nakajima H and Chiorini JA: Autophagy as a modulator of cell death
machinery. Cell Death Dis. 11(517)2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Kang R, Zeh HJ, Lotze MT and Tang D: The
Beclin 1 network regulates autophagy and apoptosis. Cell Death
Differ. 18:571–580. 2011.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Guo GF, Wang YX, Zhang YJ, Chen XX, Lu JB,
Wang HH, Jiang C, Qiu HQ and Xia LP: Predictive and prognostic
implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment
combined with chemotherapy in advanced colorectal cancer with
wild-type KRAS: Analysis from real-world data. World J
Gastroenterol. 25:1840–1853. 2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Guo JY, Xia B and White E:
Autophagy-mediated tumor promotion. Cell. 155:1216–1219.
2013.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Bellodi C, Lidonnici MR, Hamilton A,
Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi
T, Yacobi R, et al: Targeting autophagy potentiates tyrosine kinase
inhibitor-induced cell death in Philadelphia chromosome-positive
cells, including primary CML stem cells. J Clin Invest.
119:1109–1123. 2009.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Li H, Jin X, Zhang Z, Xing Y and Kong X:
Inhibition of autophagy enhances apoptosis induced by the
PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Cell Biochem Funct. 31:427–433. 2013.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Lin CJ, Lee CC, Shih YL, Lin TY, Wang SH,
Lin YF and Shih CM: Resveratrol enhances the therapeutic effect of
temozolomide against malignant glioma in vitro and in vivo by
inhibiting autophagy. Free Radic Biol Med. 52:377–391.
2012.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Chen X, Xu H, Yu X, Wang X, Zhu X and Xu
X: Apigenin inhibits in vitro and in vivo tumorigenesis in
cisplatin-resistant colon cancer cells by inducing autophagy,
programmed cell death and targeting m-TOR/PI3K/Akt signalling
pathway. J BUON. 24:488–493. 2019.PubMed/NCBI
|
|
48
|
Tan S, Shi H, Ba M, Lin S, Tang H, Zeng X
and Zhang X: miR-409-3p sensitizes colon cancer cells to
oxaliplatin by inhibiting Beclin-1-mediated autophagy. Int J Mol
Med. 37:1030–1038. 2016.PubMed/NCBI View Article : Google Scholar
|
|
49
|
He Y, Zhang L, Tan F, Wang LF, Liu DH,
Wang RJ and Yin XZ: MiR-153-5p promotes sensibility of colorectal
cancer cells to oxaliplatin via targeting Bcl-2-mediated autophagy
pathway. Biosci Biotechnol Biochem. 84:1645–1651. 2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Cernigliaro C, D'Anneo A, Carlisi D,
Giuliano M, Gammazza AM, Barone R, Longhitano L, Cappello F,
Emanuele S and Distefano A: Ethanol-mediated stress promotes
autophagic survival and aggressiveness of colon cancer cells via
activation of Nrf2/HO-1 pathway. Cancers (Basel).
11(505)2019.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Schaaf MB, Keulers TG, Vooijs MA and
Rouschop KM: LC3/GABARAP family proteins: autophagy-(un)related
functions. FASEB J. 30:3961–3978. 2016.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Vera-Ramirez L, Vodnala SK, Nini R, Hunter
KW and Green JE: Autophagy promotes the survival of dormant breast
cancer cells and metastatic tumour recurrence. Nat Commun.
9(1944)2018.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Ma J, Dong C and Ji C: MicroRNA and drug
resistance. Cancer Gene Ther. 17:523–531. 2010.PubMed/NCBI View Article : Google Scholar
|
